Results of Analysis of Co-variance (ANCOVA) for change in parameter predicted by treatment group with pre-treatment value as a covariate. * p < 0.05; ** p < 0.01. by Lijuan Liu (136685)

Subjects:

Comparison of treatment effects between premolar extraction and mandibular third molar extraction groups. * p < 0.05; ** p < 0.01. by Lijuan Liu (136685)

Subjects:

Intraoperative facial and intraoral photographs of the case with mandibular third molar extraction. by Lijuan Liu (136685)

Subjects:

Pretreatment facial, intraoral photographs, and radiographs of the case with premolar tooth extraction. by Lijuan Liu (136685)

Subjects:

Pretreatment facial, intraoral photographs, and radiographs of the case with mandibular third molar extraction. by Lijuan Liu (136685)

Subjects:

Active DNA Demethylation Mediated by <i>OsGADD45a2</i> Regulates Growth, Development, and Blast (Magnaporthe oryzea) Resistance in Rice by Ganghua Zhou (9283406)

“…In <i>OsGADD45a2</i> overexpression lines, significant decreases in CG and CHG methylation levels were observed in protein-coding genes, leading to their upregulation. …”

The results of KEGG enrichment analysis (Annotation: Circles represent each pathway, and the redder the color, the larger the circle, and the more important it is). by Lin Zhou (141050)

Traits at cellular, leaf, and whole-plant scales which were significantly different [increased (↑) or decreased (↓)] or non-significant between tolerant and sensitive cultivars in... by Ranjeeta Adhikari (9905958)

CBP per cumulative year for daratumumab and pembrolizumab per vial. by R. J. S. D. Heine (17889199)

Subjects:

S4 Fig - by R. J. S. D. Heine (17889199)

Subjects:

S1 Fig - by R. J. S. D. Heine (17889199)

Subjects:

S5 Fig - by R. J. S. D. Heine (17889199)

Subjects:

Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial. by R. J. S. D. Heine (17889199)

Subjects:

S3 Fig - by R. J. S. D. Heine (17889199)

Subjects:

S6 Fig - by R. J. S. D. Heine (17889199)

Subjects:

CBP per cumulative indication for daratumumab and pembrolizumab per vial. by R. J. S. D. Heine (17889199)

Subjects:

Inputs utilized in base-case and scenario analysis for daratumumab and pembrolizumab, both unadjusted and adjusted for PPP and inflation. by R. J. S. D. Heine (17889199)

Subjects:

Implementation of indication-based pricing (10^th scenario) for daratumumab and pembrolizumab. by R. J. S. D. Heine (17889199)

Subjects:

Scenario analysis for daratumumab using a cumulative cost-based price per year per vial. by R. J. S. D. Heine (17889199)

Subjects:

Input parameters for the base-case analysis. by R. J. S. D. Heine (17889199)

Subjects: